Drug intelligence / Profile preview

PT-627

Development stage: Preclinical
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PT-627 is a monoclonal antibody that acts as an agonist of programmed cell death protein 1 (PD-1, also known as CD279). It was initially developed by Pandion Therapeutics, which is now a subsidiary of Merck & Co. The drug is designed to activate PD-1 signaling, thereby suppressing overactive T cell responses and modulating immune activation pathways such as Th1/Th2 and Th17 differentiation. This mechanism positions PT-627 as a potential treatment for autoimmune diseases by attenuating excessive immune activity[1][2][6]. In preclinical studies and cell-based assays, PT-627 demonstrated the ability to suppress multiple immune activation pathways relevant to autoimmunity[6].

Other names: Systemic PD-1 agonist

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on PT-627.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PT-627.

Explore the full profile